EUVIMEDEUVIMED entdecken
Crossref

Atraric Acid Mitigates Mitochondrial Dysfunction and Inflammation via AMPKα–PGC-1α Signaling in Metabolic-Associated Fatty Liver Disease

Yannan Xiang, Zhihao Ma, Tianyue Guan, Hongyu Huang, Xinran Li, Zihan Xu, Panpan Zhao, Lei Wang

Antioxidants & Redox Signaling · 01.03.2026 · 44 (7-9) · 332-356

DOI: 10.1177/15230864251406293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antioxidants & Redox Signaling, online erschienen am 30.12.2025. Verfasst von Yannan Xiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroscience, Department of Neurosurgery, Lianyungang Clinical College of Nanjing Medical University, the Affiliated Lianyungang Hospita…. Hauptthemen laut MEDLINE: Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, AMP-Activated Protein Kinases, Signal Transduction, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic-associated fatty liver disease (MASLD) is a leading cause of chronic liver injury worldwide, characterized by hepatic lipid accumulation, oxidative stress, inflammation, and mitochondrial dysfunction. Despite its prevalence, no approved pharmacological treatments currently exist. Atraric acid (AA), a natural compound with antioxidant and anti-inflammatory properties, has not been previously investigated in MASLD.

Objective

This study aimed to evaluate the therapeutic potential of AA and elucidate its underlying mechanisms in MASLD.

Methods

MASLD was modeled in mice using a high-fat diet and in alpha mouse liver 12 hepatocytes using oleic acid/palmitic acid. AA’s effects on liver injury, mitochondrial function, and inflammatory signaling were assessed through biochemical assays, histology, transcriptomic analysis, and mechanistic studies involving adenosine 5′-monophosphate-activated protein kinase (AMPK) inhibition and liver-specific AMPK knockout models.

Results

AA significantly improved hepatic steatosis, reduced serum alanine transaminase and aspartate aminotransferase levels, and alleviated inflammation in MASLD mice. In vitro , AA restored mitochondrial membrane potential, enhanced adenosine triphosphate production, and suppressed reactive oxygen species accumulation and NOD-, LRR-, and pyrin domain-containing protein 3 inflammasome activation. Mechanistically, AA directly interacted with AMPK, promoted its phosphorylation, and upregulated peroxisome proliferator-activated receptor γ coactivator 1 alpha (PGC-1α), thereby improving mitochondrial biogenesis and redox balance. These protective effects were abolished by AMPKα inhibition or knockout, confirming AMPK as a key mediator. Additionally, AA modulated related pathways, including SIRT1 and mTOR, suggesting broader metabolic benefits.

Conclusion

AA mitigates MASLD by activating the AMPK–PGC-1α axis, restoring mitochondrial function, and reducing ROS-driven inflammation. These findings highlight AA as a promising candidate for MASLD therapy and warrant further clinical investigation. Antioxid. Redox Signal. 44, 332–356.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaAMP-Activated Protein KinasesSignal TransductionInflammationMitochondriaFatty LiverAnimalsMiceMaleDisease Models, AnimalOxidative StressHepatocytes

Stichwörter der Autor:innen

AMPK-αMASLDPGC-1αROSatraric acidmitochondrial dysfunction

Substanzen

Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaAMP-Activated Protein KinasesPpargc1a protein, mouse

Autor:innen und Institutionen

  • Institute of Neuroscience, Department of Neurosurgery, Lianyungang Clinical College of Nanjing Medical University, the Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyun…
  • Jiangsu Marine Pharmaceutical Resources Development Engineering Research Center, Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, China.
  • Department of Laboratory Medicine, Lianyungang Clinical College of Nanjing Medical University, the Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Lianyungang, C…

Zitieren

APA

Xiang, Y., Ma, Z., Guan, T., Huang, H., Li, X., Xu, Z., Zhao, P., & Wang, L. (2026). Atraric Acid Mitigates Mitochondrial Dysfunction and Inflammation via AMPKα–PGC-1α Signaling in Metabolic-Associated Fatty Liver Disease. Antioxidants & Redox Signaling, 44(7-9), 332-356. https://doi.org/10.1177/15230864251406293

Vancouver

Xiang Y, Ma Z, Guan T, Huang H, Li X, Xu Z, et al. Atraric Acid Mitigates Mitochondrial Dysfunction and Inflammation via AMPKα–PGC-1α Signaling in Metabolic-Associated Fatty Liver Disease. Antioxidants & Redox Signaling. 2026;44(7-9):332-356. doi:10.1177/15230864251406293

BibTeX
@article{Xiang2026,
  author = {Xiang, Yannan and Ma, Zhihao and Guan, Tianyue and Huang, Hongyu and Li, Xinran and Xu, Zihan and Zhao, Panpan and Wang, Lei},
  title = {Atraric Acid Mitigates Mitochondrial Dysfunction and Inflammation via AMPKα–PGC-1α Signaling in Metabolic-Associated Fatty Liver Disease},
  journal = {Antioxidants & Redox Signaling},
  year = {2026},
  volume = {44},
  number = {7-9},
  pages = {332--356},
  doi = {10.1177/15230864251406293}
}
Kostenlos starten →